17results about "Angiotensins" patented technology

The invention provides gRNA (guide Ribonucleic Acid) targeting an AGT (Absorption Growth Tube) gene and application thereof, in particular, the invention provides gRNA targeting an AGT gene exon-intron splicing junction region, the invention firstly discovers that the gRNA designed by targeting the AGT gene splicing junction region (such as an intron 1 receptor, an intron 2 donor / receptor and an intron 4 donor / receptor) can effectively inhibit the expression of the AGT gene, therefore, the gRNA can be used for inhibiting the expression of the AGT gene. According to the gRNA designed by the invention, the gene editing efficiency can be remarkably improved; and / or treating a disease.

The embodiment of the invention discloses an angiotensin II-1 type receptor polypeptide or a fusion compound and application of the angiotensin II-1 type receptor polypeptide or the fusion compound. The invention provides an angiotensin type 1 receptor polypeptide or fusion, which is coated in a solid phase material (porous plate, magnetic beads, agarose particles, latex particles and the like) and is used for detecting an antibody aiming at an angiotensin II-1 receptor in the body of a patient suffering from diseases such as eclampsia and the like. The compound can also be used for blocking the combination of autoantibodies in the bodies of pregnant women and angiotensin II-1 type receptors, and treating various cardiovascular diseases such as dilated cardiomyopathy, just-gauge disease, heart failure and the like.

Provided herein are dosage forms and kits comprising angiotensin II that are suitable for the treatment of low blood pressure. In particular, dosage forms and kits that facilitate the ability to rapidly prepare angiotensin II for IV infusion into a subject.

The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and / or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and pain.

Methods and materials for treating or preventing cardiotoxicity and / or hypertension induced by one or more anti-cancer agents (e.g., tyrosine kinase inhibitor (TKI) -induced cardiotoxicity (e.g., sunitinib-induced cardiotoxicity) and / or TKI-induced hypertension (e.g., sunitinib-induced hypertension)) are provided herein. For example, provided herein are methods for using polypeptides (e.g., chimeric polypeptides) that include (a) one or more natriuretic peptides and (b) one or more angiotensin 1-7 (ANG1-7) polypeptides to treat or prevent cardiotoxicity and / or hypertension induced by one or more anti-cancer agents.

The present disclosure provides a method of mitigating amyloid-related imaging abnormalities in a subject receiving an antibody therapy, such as a monoclonal antibody, for the treatment of Alzheimer's disease by administering an effective amount of an Angiotensin-(1 -7) receptor agonist to the subject.

The present invention provides an angiotensin-(1-9) analog, particularly an angiotensin-(1-9) peptide synthesized from D-amino acids. This invention further involves the inversion of the original sequence of angiotensin-(1-9). This analog possesses an increased stability and maintains the biological activity of angiotensin-(1-9). Another embodiment of this invention comprises pharmaceutical compositions containing said analog and their use in the treatment of cardiovascular diseases, tissue remodeling in kidney, brain, and also the induction of cardioprotection.

Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.

Provided are methods for treating subjects with coronavirus infections. The methods include providing a subject infected with a coronavirus resulting in a prothrombotic condition in addition to being infected by a coronavirus, and administering to the subject an angiotensin (1-7) peptide or an analog or derivative thereof, a Mas Receptor (MasR) agonist, or any combination thereof. The subject may be suffering from COVID-19 disease, including but not limited to a thrombotic complication, an adverse pregnancy outcome, and / or a complication resulting from an underlying prothrombotic state. Also provided are compositions that include Ang (1-7) peptides, analogs, and / or derivatives thereof that are associated with degradable and / or non-degradable polymers having electrostatic interactions therewith, hydrophobic interaction therewith, hydrogen bonding interactions therewith, or any combination thereof. Also provided are uses of Ang (1-7) peptides, analogs, and / or derivatives thereof and / or a Mas Receptor (MasR) agonists for treating subjects infected with coronaviruses and / or for preparing medicaments therefore.

Disclosed herein is a split intein system including a first nucleic acid molecule encoding a fusion protein including an N-extein of an extein pair and an N-intein of an intein pair, where the N-extein includes a first signal sequence N-terminal to an N-terminal portion of a type IV collagen alpha chain. Also disclosed is a second nucleic acid molecule encoding a fusion protein including a second signal sequence, a C-intein of the intein pair, and a C-extein of the extein pair, where the C-extein includes a C-terminal portion of the type IV collagen alpha chain. Further disclosed are AAV vectors including the nucleic acid molecules, and methods of using the AAV vectors or nucleic acid molecules to treat a subject with Alport syndrome.

Provided are a gRNA targeting an AGT gene and a use thereof, and in particular, provided is a gRNA targeting an exon-intron splicing junction region of the AGT gene. The gRNA designed to target the exon-intron splicing junction region of the AGT gene (e.g., an intron 1 acceptor, an intron 2 donor / acceptor, and an intron 4 donor / acceptor) can effectively inhibit the expression of the AGT gene.

The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and / or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and / of impairment.

The present invention relates to a novel peptide having binding affinity to ACE2 and uses thereof and, more specifically, to: a peptide represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 4, and having binding affinity to ACE2; a nanocarrier and a drug complex, each comprising the peptide; and a pharmaceutical composition for preventing or treating COVID-19, comprising the peptide, the nanocarrier, or the drug complex. The novel peptide according to the present invention can be used to increase the COVID-19 therapeutic effect through specific binding to ACE2-expressing cells.

The present invention provides an angiotensin-(1-9) analog, particularly an angiotensin-(1-9) peptide synthesized from D-amino acids. This invention further involves the inversion of the original sequence of angiotensin-(1-9). This analog possesses an increased stability and maintains the biological activity of angiotensin-(1-9). Another embodiment of this invention comprises pharmaceutical compositions containing said analog and their use in the treatment of cardiovascular diseases, tissue remodeling in kidney, brain, and also the induction of cardioprotection.

The present invention relates to a peptide agonist of the Mas, AT1 and AT2 receptors, having amino acid sequence SEQ ID NO: 1, which is useful in preventing and / or treating hypertension, and / or reducing cardiovascular, cerebral, pulmonary and renal vasoconstriction, and / or preventing, reversing, inhibiting and / or reducing the pathological remodelling of cardiovascular, pulmonary, renal and / or cerebral tissue. The invention also relates to a pharmaceutical composition comprising the peptide or a combination of the peptides, useful in preventing and / or treating hypertension, reducing vascular vasoconstriction, and / or preventing, reversing, inhibiting and / or reducing the pathological remodelling of cardiovascular, pulmonary, renal and / or cerebral tissue.

The present invention relates to a phosphated p-hydroxyphenylhydrazine compound and a method for assisting in the preparation of Ang1-7 peptide compounds, belonging to the technical field of organic synthesis. The structural general formula of PPHPH is as follows. The present invention also provides an application of the phosphated p-hydroxyphenylhydrazine compound PPHPH in the preparation of Ang1-7 peptide compounds, and a method for assisting in the preparation of Ang1-7 peptide compounds with the phosphated p-hydroxyphenylhydrazine compound PPHPH. The present invention combines the advantages of liquid-phase and solid-phase synthesis methods, and can synthesize and prepare Ang1-7 peptides more simply, quickly, economically and efficiently. Moreover, the PPHPH carrier residue can be recovered and directly reused, reducing waste of raw materials, reducing waste pollution, saving costs and being environmentally friendly.

The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and / or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and / of impairment.